FAG
FENC icon

Fortitude Advisory Group’s Fennec Pharmaceuticals FENC Stock Holding History

Fortitude Advisory Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,500
Closed -$8K – 571
2022
Q1 		$8K Hold
1,500
– – ﹤0.01% 1061
2021
Q4 		$7K Buy
+1,500
New +$11.2K ﹤0.01% 1121

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fortitude Advisory Group's FENC Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Fennec Pharmaceuticals (FENC) in Q2 2022, closing a stake of 1,500 shares — an estimated $8K sold.

Fortitude Advisory Group first reported a position in FENC in Q4 2021 and held it in 2 quarters. The position peaked at $8K in Q1 2022. 28 funds tracked by Wall St. Rank hold FENC as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Fennec Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 1,500 Fennec Pharmaceuticals shares in Q2 2022, an estimated $8K.
  • Fortitude Advisory Group first reported a position in Fennec Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Fennec Pharmaceuticals position peaked at $8K in Q1 2022.
  • 28 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.